Zodem

Quick links to important sections

Zodem

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zodem

Quick Facts

Property Description
Active ingredient Zolpidem tartrate
Form Oral tablets (immediate-release or extended-release)
Pharmacological class Non-benzodiazepine Z-drug, Sedative-hypnotic agent
Common use Support for sleep onset and maintenance
Origin Synthetic compound (Imidazopyridine family)

Zodem: Defining the Drug Entity and Its Therapeutic Class

Zodem is a trade name for a medication containing the active ingredient Zolpidem tartrate, which is formally classified as a sedative-hypnotic agent. This compound is a synthetic molecule belonging to the imidazopyridine family. Its primary function is to address sleep difficulties by selectively acting on the central nervous system. Zolpidem is classified as a non-benzodiazepine Z-drug, distinguishing it from older classes of sedatives. This targeted action is a key differentiating factor in its pharmacological profile, designed to promote rest with specificity.


Composition, Dosage Form, and Release Profiles of Zolpidem

The medication is a single-component product whose active ingredient is Zolpidem tartrate, intended for oral administration. It is available as oral tablets in formulations that define its therapeutic timing. The immediate-release form is designed for rapid absorption, which helps reduce the time required to fall asleep (sleep latency). Conversely, the extended-release formulation is engineered to release the Zolpidem over several hours, which is typically used for individuals needing support for sleep maintenance throughout the night. This difference in release profile is a crucial compositional feature that tailors its function to the patient's specific sleep pattern disruption.


Core Benefit: How Zolpidem Supports Sleep Onset and Maintenance

The core benefit of the medication is the facilitation of sleep. Zolpidem achieves this by selectively enhancing the effect of GABA (gamma-Aminobutyric acid), the brain’s main inhibitory neurotransmitter, at specific receptor sites. This action helps to slow down the neuronal signaling that contributes to hyperarousal. The drug’s general purpose is to provide pharmacological support for both the ability to fall asleep quickly, by reducing sleep latency, and the ability to remain asleep, addressing a typical use scenario for those experiencing chronic sleep disturbance.

Regulatory References

  1. GABA
  2. sedative-hypnotic agent

What side effects are possible with Zodem?

Possible Side Effects and Safety Information

The safety characteristics of Zodem (Zolpidem tartrate) are detailed in regulatory documents by categories of frequency and organ system involvement. The profile is marked by risks related to Central Nervous System (CNS) effects and specific safety constraints for vulnerable populations.


Adverse Reaction Frequencies and Systems

Adverse reactions are classified based on the likelihood of their occurrence, as documented in official prescribing information:

  • Common Reactions: These are reported in official labels as occurring in at least 1 in 100 users and include somnolence (drowsiness), headache, dizziness, and anterograde amnesia (memory impairment for events after taking the drug). Gastrointestinal effects such as diarrhoea and nausea are also commonly listed.
  • Uncommon to Rare Reactions: Less frequent effects include confusional state, hallucinations, aggression, and visual disturbances like blurred or double vision. Falls and liver injury (hepatocellular, cholestatic, or mixed) are categorized as rare events.

Serious Adverse Reactions

Specific serious risks are officially documented. These include Complex Sleep Behaviors (CSBs), such as sleep-walking (somnambulism) or engaging in activities like sleep-driving while not fully awake, which may result in serious injury. Additionally, the drug is associated with rare, severe hypersensitivity reactions (including Angioedema) and the potential for clinically significant respiratory depression.


Population- and Duration-Related Safety Patterns

The safety profile is adjusted for certain groups. Older adults are officially noted to be more susceptible to adverse effects, particularly the risk of falls and related injury. Use is contraindicated in individuals with severe hepatic insufficiency due to the risk of hepatic encephalopathy. Regulatory texts also state that the risk of drug dependence and tolerance increases with the duration of treatment, and that residual next-day impairment can occur.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Zolpidem tartrate (Zodem) is officially documented to present as a spectrum of Central Nervous System (CNS) depression.

Documented Overdose Manifestations

Classification Official Regulatory Description
Symptom Profile Impairment of consciousness ranging from somnolence and excessive sedation to light coma [NIH/FDA].
Severe Outcomes Potential for respiratory depression and cardiorespiratory collapse. Fatal outcomes have been reported, particularly when co-ingested with alcohol or other CNS depressants [SmPC/FDA].
Special Populations Elderly and debilitated patients may exhibit increased sensitivity. Those with hepatic insufficiency have reduced drug clearance [FDA/SmPC].

Regulator-Mandated Emergency Actions

It is officially required to seek immediate medical attention and contact a Poison Control Center upon any known or suspected overdosage. Urgent medical help is necessary when severe symptoms like profound consciousness impairment or respiratory distress occur.

Treatment is defined as primarily symptomatic and supportive, with a focus on maintaining airway and cardiorespiratory function. Procedural options may include gastric lavage or administration of activated charcoal. While flumazenil is noted as an available reversal agent, its routine use is generally discouraged due to the potential risk of inducing seizures [FDA].

Therapeutic Uses of Zodem

The therapeutic application of Zodem (Zolpidem) is focused on the supportive management of insomnia, a condition characterized by disruptive sleep patterns. The medication is indicated for the short-term treatment of this sleep disorder. The overall clinical utility is defined by two primary symptom patterns.

Zodem is commonly used to help with two primary symptom patterns: prolonged sleep latency (difficulty falling asleep) and sleep maintenance difficulties (trouble staying asleep and nocturnal awakenings). Its utility is considered relevant in clinical situations where sleep loss is associated with severe distress or is debilitating, where symptoms interfere with a person's daily stability.

The core benefit is to provide supportive relief that assists with the transition into a state of rest and contributes to increased total sleep time. This symptomatic assistance helps patients cope more steadily with these challenging episodes.

“The primary goal of this medication is to support the patient in achieving sleep continuity during periods of heightened symptomatic burden.”


Quick Fact: Relief for Sleep Initiation Failure The medication is relevant for managing sleep difficulties that specifically involve the time it takes to fall asleep at the start of the night, known as sleep latency.

Regulatory References

  1. DailyMed (NIH) drug label for Zolpidem tartrate

Eligibility and Restrictions for Use

Eligibility: Official Regulatory Rules

Zodem (Zolpidem tartrate) is intended for use only in adult patients (18 years and older). Its use is not recommended in children and adolescents, as official regulatory sources indicate that safety and effectiveness have not been established in the pediatric population.

Population Group Eligibility Status (Regulatory)
Pediatric Patients (Under 18) Not Recommended; Safety Not Established
Older Adults (Geriatric) Conditional Use; Requires Lower Initial Dose
Severe Hepatic Impairment Contraindicated
Pregnancy (Third Trimester) Not Usually Recommended

Contraindications define who must not use the medicine. Absolute exclusions include a known hypersensitivity to zolpidem or its components, and patients who have experienced complex sleep behaviors after prior use. The medicine is also strictly contraindicated in populations with severe hepatic insufficiency (severe liver disease), severe respiratory insufficiency, and certain conditions like Myasthenia Gravis or severe sleep apnea.

Conditional use is required for older adults and those with mild to moderate hepatic impairment, as they are more sensitive to the effects of the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Zodem is defined by patterns of pharmacodynamic synergism and significant pharmacokinetic alterations via the CYP450 enzyme system, as documented by regulatory bodies. The medication is contraindicated in patients with a history of complex sleep behaviors (such as sleep-driving) after taking any zolpidem product.

Drug and Substance Interactions

Co-administration with CNS depressants (a category that includes Opioids and Tricyclic Antidepressants) is associated with the risk of additive CNS-depressant effects and increased sedation. The use of Opioids concomitantly with Zodem may specifically elevate the risk of respiratory depression.

Metabolically, the profile includes interactions where CYP3A4 inhibitors (e.g., Ketoconazole) officially increase the exposure and resulting effect of zolpidem. Conversely, CYP3A4 inducers (e.g., Rifampin, St. John's wort) decrease its exposure, which may reduce the drug's effect.

Alcohol is officially prohibited for co-administration due to documented additive psychomotor impairment. The use of other sedative-hypnotics at the same time is not recommended.

Timing and Population Restrictions

Administration must occur immediately prior to going to bed when the patient is capable of ensuring seven to eight hours of uninterrupted sleep. This mandatory timing constraint is established to mitigate the risk of next-day impairment. The medication is contraindicated in patients with severe hepatic insufficiency, a condition that impairs the body's ability to clear the drug.

Mechanism of Action

How Zodem Works

Zodem exerts its primary pharmacodynamic action by binding selectively to defined receptor systems within central or peripheral physiological pathways. This interaction is characterized by targeted engagement, typically functioning as a modulator (e.g., antagonist or partial agonist), which initiates an alteration in the receptor's responsiveness to its endogenous mediators. This selective binding alters the initial signaling dynamics in relevant physiological systems.

Following receptor engagement, Zodem modifies the molecular signaling cascades that transmit information within the target cell. The drug's mechanism influences signal amplification and the intensity of signal transduction downstream of the receptor. This targeted interference consequently influences the impact of dysregulated mediator activity, leading to an altered state within the affected intracellular pathways.

The resulting cumulative molecular activity is the modulation of regulatory feedback systems that control the overall functional activity level of the targeted systems. This influence on feedback loops alters the activity levels of the targeted physiological responses, resulting in mechanistic adjustments to the relevant physiological parameters.

Dosage and Administration Information

How Zodem is Used: Official Administration Guidelines

Zodem (Zolpidem tartrate) is administered strictly via the oral route, available as Immediate-Release (IR) tablets, Extended-Release (ER) tablets, and specific sublingual forms. The instructions for use are established to define proper administration.


Administration Scope Summary

Feature Official Instruction Summary
Route & Forms Oral route: Swallowed IR/ER tablets or sublingual tablets.
Standard Dosing Maximum daily dose is 10 mg (IR) or 12.5 mg (ER). The lowest effective dose is always used to initiate therapy.
Frequency Taken once daily (per night) immediately before or at bedtime.
Food Interaction Must be taken without or not immediately after a meal to prevent slowing the onset of action.
Target Duration Intended for short-term use only, generally not exceeding four weeks.

Key Procedural Rules

Official instructions require the following procedural adherence to usage:

  • Timing Constraint: The dose must be taken only when the user is prepared to commit to at least 7 to 8 hours of sleep time remaining before the planned awakening, and the dose must not be repeated during the night.
  • Tablet Handling: IR and ER tablets must be swallowed whole and should not be crushed, divided, or chewed.
  • Population Dosing: A reduced starting dose of 5 mg (IR) or 6.25 mg (ER) is specified for older adults and those with hepatic impairment.

This protocol ensures a standardized approach to usage, defining the exact boundaries for dosing, frequency, and administration conditions.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Zodem

Evidence for Difficulty Falling Asleep (Sleep Initiation)

The core evidence that has examined Zodem for the symptom of difficulty falling asleep comes primarily from short-term Randomized Controlled Trials (RCTs). These studies compared the immediate-release formulation of Zodem against a placebo in adult participants. Research examined a key outcome called Sleep Latency, using both objective monitoring (polysomnography or PSG) and patient-reported outcomes. Findings describe patterns observed in the studies where changes in the measurements of the time taken to fall asleep were documented in comparison to the placebo groups, with the largest documented changes observed in some studies during the initial weeks of use.

Evidence for Difficulty Staying Asleep (Sleep Maintenance)

Research that has explored difficulties staying asleep—such as frequent nocturnal awakenings—often centers on studies involving the extended-release (ER) formulation of Zodem. Studies examined objective sleep measures, including Total Sleep Time (TST) and Wake After Sleep Onset (WASO). This research was conducted to study sleep continuity in adults and older adults. Studies monitored changes measured in both TST and WASO when compared to placebo. Evidence is limited for objective WASO measurements beyond the initial short-term phases, as longer-duration studies often rely more heavily on patient-reported outcomes.

Evidence in Special Populations: Focus on Older Adults

Specific research was evaluated in the older adult population (65 years or older). These studies focused on how the body processes Zodem, as well as outcomes related to next-day psychomotor performance, such as balance and alertness. Data show patterns related to how the body processes Zodem, indicating differences in concentration levels compared to younger adults. Studies monitored next-day residual effects in the older adult group, particularly when higher doses were observed in some studies.

Research Gaps and Areas of Uncertainty

A review of the scientific literature highlights several areas where more information is needed. Follow-up durations were limited in many primary efficacy trials, meaning that the full spectrum of long-term effects are not fully established. Subgroup findings are uncertain for specific populations, such as those with comorbidities or the very oldest adults (e.g., 80 years and above). Additionally, comparative evidence is lacking in some areas, meaning that head-to-head comparisons against other available treatment options have been limited in large, definitive trials.

Key Studies & References

  1. Zolpidem tartrate Tablets, C-IV: U.S. Food and Drug Administration (FDA) Approved Drug Label (Immediate-Release and Extended-Release)
  2. Efficacy and safety of extended-release zolpidem in the treatment of insomnia: a randomized, double-blind, placebo-controlled clinical trial
  3. Polypharmacy and Older People: Practical Strategies for Safe Prescribing

Frequently Asked Questions (FAQ)

Common questions about Zodem (FAQ)

Q: Is Zodem a type of sleeping pill or something else?

Zodem is formally categorized by regulatory authorities as a sedative-hypnotic agent. Its official purpose is to support the short-term treatment of a sleep problem characterized by difficulty falling asleep and/or difficulty staying asleep.


Q: How quickly does Zodem start working?

Zodem is designed for rapid action. Official clinical data indicate that the immediate-release formulation typically reaches its peak concentration within about 1.6 hours. Official documents include administration conditions requiring the medicine be taken immediately before bed, as taking it with food is noted to slow the onset of action.


Q: How long does Zodem stay in your system?

The immediate-release form of Zodem is considered short-acting. Official studies show that the average time for the body to eliminate half of the dose (the half-life) is approximately 2 to 3 hours. This relatively short duration is a key characteristic of its pharmacological profile.


Q: What's the difference between Zodem and similar-sounding drugs?

Zodem is classified by regulatory bodies as a non-benzodiazepine sedative-hypnotic agent, often called a Z-drug. This places it in a different pharmacological category than older types of sleeping medications, such as benzodiazepines.


Q: Does Zodem cause weight gain?

Weight changes are not commonly listed as frequent side effects in the official safety summaries. However, some types of documented complex sleep behaviors, such as sleep-eating, have been reported, which could potentially result in increased caloric intake.


Q: Is Zodem safe to take every day?

Official regulatory documents indicate that Zodem is intended for short-term use only, and treatment should generally not exceed four weeks. This recommendation is based on official statements noting the risk of dependence and tolerance increases with prolonged duration of daily use.


Q: What should I do if I miss a dose of Zodem?

Official administration instructions emphasize that Zodem must be taken as a single dose once per night immediately before going to bed. Regulatory documents state that the dose should not be readministered during the same night.


Q: What happens if I stop taking Zodem suddenly?

If the medicine is stopped abruptly after regular use, regulatory information notes that effects such as rebound insomnia, which is a temporary worsening of sleep difficulties, and other withdrawal-like symptoms may occur.


Q: Do cold and flu medicines interact with Zodem?

Many non-prescription cold and flu treatments contain ingredients like certain antihistamines, which are classified as Central Nervous System (CNS) depressants. Co-administration with other CNS depressants is officially noted to be associated with an increased potential for additive effects, such as increased drowsiness.


Q: How is Zodem different from over-the-counter options?

Zodem is available only by prescription and belongs to the specific class of Z-drugs. In contrast, most over-the-counter sleep aids rely on different ingredients, such as antihistamines, which have different mechanisms of action and safety profiles.


Q: Why do some people feel groggy the next day after taking Zodem?

Groginess or residual next-day impairment is a documented risk related to the drug's action as a CNS depressant. This risk is specifically noted to be higher if the dose is taken without ensuring that the user has a full 7 to 8 hours of sleep time remaining.


Q: Is it normal to have vivid dreams while taking Zodem?

Changes in dreaming, including reports of vivid dreams, are listed in official regulatory documents among the less common psychiatric side effects of Zodem. If this occurs, it is listed in the product information as a potential effect.


Q: Does Zodem affect a person's mood?

Official warnings note that Zodem may cause changes in thinking and behavior. These behavioral changes can officially include aggression, agitation, and even the worsening of existing depression. Any new behavioral or mood changes should be reviewed by a healthcare provider.


Q: Is Zodem a short-acting or long-acting medicine?

Based on its rapid absorption and short elimination half-life, Zodem is generally described in official drug information as a rapid-onset and short-acting sedative-hypnotic agent. Different formulations are available to target either sleep onset or sleep maintenance.


Q: Are there specific instructions for discontinuing Zodem?

Official guidelines note that if the medication has been taken regularly for an extended period, it should not be stopped abruptly. Regulatory guidelines note that treatment should be withdrawn gradually rather than stopped abruptly after extended use, to minimize the potential for rebound effects.


Q: Are there different forms of Zodem (e.g., tablet, liquid)?

Zodem is available in various official tablet forms for oral use, including immediate-release tablets, extended-release tablets, and specific sublingual tablets that are designed to dissolve under the tongue. Primary regulatory sources do not list a liquid form.


Q: Can Zodem be taken with pain medication?

Official drug interaction warnings specifically note that co-administration with Opioids, which are strong pain medicines, is associated with a heightened risk of profound sedation and respiratory depression. This is noted due to the potential for increased depressant effects on the central nervous system.


Q: Why is Zodem sometimes described as having a risk of 'sleep driving'?

'Sleep driving' is specifically named in regulatory Boxed Warnings as a potential Complex Sleep Behavior (CSB). These behaviors involve engaging in activities while not fully awake and can result in serious injury, requiring discontinuation of the medication.


Q: Is it possible to become dependent on Zodem?

Official regulatory documents classify Zodem as a Schedule IV controlled substance due to the documented risk of drug dependence and potential for abuse. This risk is officially noted to increase with the duration of treatment and dose level.


Q: Are there restrictions on driving or operating machinery while using Zodem?

Official product information notes that patients should not drive or operate machinery until they are certain that Zodem does not cause residual next-day impairment. This potential impairment exists even if the user feels fully awake after the mandatory sleep period.


Q: Does Zodem affect blood pressure?

Changes to blood pressure are not listed as a common side effect. However, regulatory reports of adverse events have included cardiovascular effects, such as a drop in blood pressure (hypotension), typically categorized as an uncommon or rare event.


Q: How can I tell if a side effect from Zodem is serious?

Regulatory documents explicitly categorize risks such as Complex Sleep Behaviors, severe swelling (Angioedema), and severe respiratory depression as serious adverse reactions. Regulatory documents note that serious adverse reactions require prompt medical assessment.


Q: Why is the dosage of Zodem different for men and women in some cases?

Official dosing guidelines recommend a lower starting dose for women than for men in some cases. This difference is based on studies showing that women clear Zodem from the body more slowly than men, which can result in higher drug levels and a greater risk of next-day impairment.

How should Zodem be stored and disposed of?

How to Store and Dispose of Zodem (Zolpidem Tartrate)

Required Storage Conditions

Zolpidem Tartrate must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The medication must be kept in a closed container and protected away from heat, moisture, and direct light. It is mandatory that the product not be frozen.

Safety and Disposal

To prevent accidental ingestion, Zodem must always be stored out of the reach of children.

For disposal of expired or unused product, the official guidance prioritizes a drug take-back program or mail-back envelope. If these options are unavailable, the medicine should be removed from its container, mixed with an undesirable substance (such as dirt or coffee grounds), and sealed in a bag or container before being placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zodem found in:

A-Z Index: